Osteopore Accelerates Growth with $20M Funding and Strategic Stem Cell Partnerships

• 27% year-over-year revenue growth in CY24 despite Q4 operational challenges
• Collaboration agreements signed with RxCell and CytoMed to advance scaffold-based and MSC-powered regenerative therapies
• Strategic investment in Regen SPV with leading regenerative medicine scientists
• Exclusive distribution deals secured in Brazil and Singapore to expand craniofacial and orthopaedic product reach